📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-12 15:09
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Shalby Shareholders Reject Appointment of Shanay Shah as Whole-Time Director
Shalby Limited announced that shareholders rejected the ordinary resolutions for appointing Mr. Shanay Vikram Shah as Director and Whole-time Director at the 22nd AGM. The voting results declared on September 11, 2026, failed to secure the requisite majority despite the promoter group holding a 74.33% stake. Consequently, Mr. Shah automatically ceased to be an Additional Director effective September 10, 2026, though he will continue in his role as President of the Company.
Confidence: HIGH
What changedShanay Vikram Shah ceased to hold office as an Additional Director designated as Whole-time Director effective September 10, 2026, after shareholders defeated the AGM resolution.
Why it mattersA board appointment failure at a listed company with 74.33% promoter holding signals rare governance friction or voting non-participation, creating uncertainty over top management succession.
Effective cessation date: September 10, 2026AGM voting results declared date: September 11, 2026Board approval date: August 12, 2026Promoter holding: 74.33%
📅 Short termMay lead to negative market sentiment regarding corporate governance and institutional alignment given the defeated management resolution.
📈 Long termLeadership dynamics and governance oversight will remain scrutinized, although operational continuity is partially preserved through his executive role as President.
⚠ Risk flags
- Shareholder-promoter misalignment or governance pushback
- Key management succession uncertainty
Key Highlights
Ordinary Resolutions 3 and 4 for the appointment of Shanay Vikram Shah failed to get requisite shareholder approval
Cessation as Additional Director/Whole-time Director took effect retrospectively from September 10, 2026
Shanay Vikram Shah will continue to act in an executive capacity as President of Shalby
Promoter holding stands at 74.33%, indicating notable pushback from public or institutional shareholders
👀 What to Watch
Watch for detailed AGM voting disclosures to understand the split between promoter and institutional/public votes, and monitor any subsequent board restructuring announcements.
Shalby AGM: Shareholders Reject Appointment of Shanay Shah as Whole Time Director with 81.7% Dissent
At Shalby Limited's 22nd AGM held on September 10, 2026, shareholders approved the adoption of FY26 financial statements and cost auditor remuneration. However, resolutions regarding the appointment of Shanay Vikram Shah as Director and Whole Time Director (effective August 12, 2026) were defeated. Because promoters were considered interested and did not vote their 8,02,83,373 shares, institutional and public non-institutional votes decided the outcome, resulting in 81.71% (2,50,408 votes) dissenting against the appointments. Only 18.29% (56,067 votes) backed the resolutions, highlighting significant public and institutional pushback on board composition.
Confidence: HIGH
What changedShareholders formally rejected the board appointment and 5-year executive directorship of Shanay Vikram Shah.
Why it mattersThe rejection reflects strong institutional and public shareholder opposition to promoter succession or remuneration proposals when interested promoters are recused from voting.
Dissent on WTD appointment: 81.71%Institutional votes against: 2,36,980Votes in favor of WTD appointment: 56,067Adoption of accounts approval: 99.98%
📅 Short termMay weigh on governance perception as institutional investors openly blocked an executive appointment; watch for management's response or alternate appointments.
📈 Long termSignals heightened scrutiny by institutional shareholders over promoter appointments and executive governance structures.
⚠ Risk flags
- Governance friction between promoter family and institutional shareholders
- Management succession uncertainty
Key Highlights
Resolutions 3 and 4 to appoint Shanay Vikram Shah as Director and Whole Time Director for 5 years were defeated with 81.71% votes against.
Promoter group (holding 8,02,83,373 shares or ~74.33% equity) was interested in Resolutions 3 & 4 and did not vote.
Institutional shareholders strongly rejected the appointment, voting 91.43% (2,36,980 votes) against.
Resolution 1 (FY26 financial statements) passed near-unanimously with 99.98% votes in favor (8,05,70,219 votes).
👀 What to Watch
Track subsequent company disclosures regarding board reconstitutions or executive leadership adjustments following the rejection of Shanay Shah's executive appointment.
Shalby Q1 FY27: Consolidated Revenue Up 11.6% YoY to ₹338.6 Cr, PAT Rises to ₹10.5 Cr
Shalby reported a consolidated revenue of ₹338.6 Cr for Q1 FY27, up 11.6% YoY compared to ₹303.4 Cr in Q1 FY26. Consolidated PAT grew to ₹10.5 Cr (PAT margin 3.1%) from ₹7.7 Cr in the prior year period, while EBITDA stood at ₹49 Cr with a margin of 14.5%. Notably, the Gurgaon unit (Shalby International) achieved EBITDA breakeven for the first time since acquisition, generating revenue of ₹26.2 Cr. The MedTech business delivered strong momentum with revenue expanding 53% YoY to ₹47 Cr, marking its fourth consecutive EBITDA-positive quarter.
Confidence: HIGH
What changedShalby released its full Q1 FY27 earnings call transcript detailing operational metrics, MedTech scaling, and turnaround milestones across units.
Why it mattersAchieving EBITDA breakeven at the Gurgaon acquisition and sustained profitability in the high-growth MedTech arm (₹47 Cr revenue) help de-risk margin expansion plans.
Consolidated Revenue (Q1 FY27): ₹338.6 crConsolidated PAT (Q1 FY27): ₹10.5 crMedTech Revenue Growth YoY: 53%Gurgaon Unit Revenue: ₹26.2 crGroup Net Debt: ₹463 cr
📅 Short termEarnings transcript reinforces operational stability, though higher government payer mix (32%) and compressed EBITDA margins (14.5% vs 16.0% YoY) may keep margin expansion gradual.
📈 Long termScaling Shalby MedTech and driving turnaround at Gurgaon hospital provide critical drivers to enhance ROCE from current ~7-10% levels.
⚠ Risk flags
- Increasing share of government schemes (32% vs 24% YoY) potentially lengthening receivables cycle
- EBITDA margin compression from 16.0% to 14.5% YoY at consolidated level
Key Highlights
Consolidated revenue grew 11.6% YoY to ₹338.6 Cr, with EBITDA at ₹49 Cr (14.5% margin)
Consolidated PAT increased to ₹10.5 Cr (margin 3.1%) vs ₹7.7 Cr in Q1 FY26
Gurgaon unit reached EBITDA breakeven with revenue of ₹26.2 Cr and ARPOB of ₹91,326
MedTech division revenue jumped 53% YoY to ₹47 Cr, maintaining positive EBITDA for 4 consecutive quarters
Net debt stood at ~₹463 Cr with a gearing ratio of 0.46x, while credit rating outlook improved from negative to stable (rated A)
👀 What to Watch
Monitor whether the Gurgaon hospital unit sustains EBITDA profitability and track the cash conversion cycle given the rising share of government business (32% vs 24% YoY).
Deepak Anand Resigns as CEO of Subsidiary Shalby Medtech w.e.f. September 4, 2026
Shalby Limited has informed the exchanges that Mr. Deepak Anand has resigned from the post of Chief Executive Officer of its wholly-owned subsidiary, Shalby Medtech Limited. The resignation was tendered via letter dated August 18, 2026, and takes effect at the close of business on September 4, 2026. The stated reason is a personal relocation abroad, with the company confirming no other material reasons. Shalby Medtech is a key segment within Shalby's broader ₹1,176 Cr TTM revenue base.
Confidence: HIGH
What changedDeepak Anand has resigned from his position as CEO of subsidiary Shalby Medtech Limited, effective September 4, 2026.
Why it mattersShalby Medtech represents a key growth vertical for the group; smooth management handover is important to maintain execution momentum in implant launches.
Effective cessation date: September 4, 2026Resignation intimation date: August 18, 2026TTM Revenue (Consolidated): ₹1176 CrMarket Cap: ₹1632 Cr
📅 Short termOrderly handover is planned until September 4, 2026; near-term financial impact is negligible.
📈 Long termLong-term performance will depend on the capability and execution strategy of incoming leadership at Shalby Medtech.
⚠ Risk flags
- Key person transition risk in the MedTech subsidiary
- Potential handover friction affecting new implant product timelines
Key Highlights
Deepak Anand resigned as CEO of wholly-owned subsidiary Shalby Medtech Limited on August 18, 2026.
Cessation is effective from the close of business hours on September 4, 2026.
Executive stated the sole reason for departure was relocating abroad for personal reasons.
👀 What to Watch
Track the appointment of a successor CEO to ensure seamless continuity in Shalby Medtech's ongoing implant commercialization and FY26 growth initiatives.
Shalby Q1 FY27: Consolidated Revenue Up 11.6% to ₹338.6 Cr; PAT Grows 36.7% YoY
Shalby Limited reported a consolidated revenue growth of 11.6% YoY to ₹338.6 Cr for Q1 FY27, driven by its core hospital business and the MedTech segment. Consolidated PAT rose 36.7% to ₹10.5 Cr, although standalone performance was weaker with PAT declining 2.4% to ₹25.1 Cr. The MedTech (implant) division contributed ₹47.17 Cr to revenue but reported a negligible EBITDA of ₹0.16 Cr. The company's consolidated ROCE remains low at 6.7%, and it carries a net debt of ₹463.6 Cr with a Debt/Equity ratio of 0.46x.
Confidence: HIGH
What changedShalby released its Q1 FY27 financial results, showing steady revenue growth but continued margin pressure at the consolidated level due to newer business verticals.
Why it mattersThe results highlight the financial impact of Shalby's diversification into implant manufacturing and the Delhi-NCR market, which are scaling in revenue but yet to contribute significantly to the bottom line.
Consolidated Revenue (Q1): ₹338.6 CrConsolidated PAT (Q1): ₹10.5 CrMedTech Revenue Contribution: 13.92%Net Debt: ₹463.6 CrConsolidated ROCE: 6.7%Debt/Equity Ratio: 0.46x
📅 Short termThe stock may see neutral to slightly cautious sentiment as the market digests the margin contraction in the standalone business and the high debt-to-equity ratio compared to previous years.
📈 Long termLong-term value depends on the company's ability to scale its MedTech division to 50% YoY growth as projected and improve occupancy at the Sanar International Hospital to boost consolidated margins.
⚠ Risk flags
- Margin compression in core standalone business
- Low profitability in MedTech segment
- Increased leverage with Net Debt at ₹463.6 Cr
- Low consolidated ROCE of 6.7%
Key Highlights
Consolidated Revenue increased 11.6% YoY to ₹3,386 million in Q1 FY27.
Consolidated PAT grew 36.7% YoY to ₹105 million, despite standalone PAT falling 2.4%.
MedTech segment contributed 13.92% of total revenue at ₹471.7 million but only ₹1.6 million in EBITDA.
Standalone EBITDA margins contracted to 18.4% from 21.6% in the same quarter last year.
Net Debt stood at ₹4,636 million as of June 30, 2026, with a Debt/Equity ratio of 0.46x.
👀 What to Watch
Investors should monitor the profitability turnaround in the MedTech and Delhi-NCR (Sanar) segments, as their current low margins are diluting the strong performance of the core hospital business. Watch for improvements in consolidated ROCE, which is currently at a modest 6.7%.
Shalby Appoints Shanay Vikram Shah as Whole-Time Director for 5-Year Term
Shalby Limited has appointed Mr. Shanay Vikram Shah as an Additional Director (Whole-time Director) for a five-year term effective August 12, 2026. Mr. Shah, aged 35, is a promoter and the son of the current Chairman and Managing Director, Dr. Vikram Shah. He has been associated with the company since 2013 and previously served as President, overseeing international business and strategy. The appointment is subject to shareholder approval at the upcoming AGM on September 10, 2026.
Confidence: HIGH
What changedMr. Shanay Vikram Shah has been elevated from President to the Board of Directors as a Whole-time Director.
Why it mattersThis formalizes succession planning within the promoter family, ensuring leadership continuity for a company where promoters hold 74.33%.
Term of appointment: 5 yearsAge of appointee: 35 yearsAGM Date: September 10, 2026Promoter holding: 74.33%
📅 Short termNeutral; the market typically expects such transitions in promoter-led healthcare firms and the news is unlikely to trigger significant price volatility.
📈 Long termStructural significance as it integrates the next generation into board-level decision-making, particularly for international and MedTech segments which are key growth drivers.
⚠ Risk flags
- Related-party appointment
Key Highlights
Appointment of Mr. Shanay Vikram Shah as Whole-time Director for a 5-year term starting August 12, 2026
Mr. Shah is 35 years old and holds a Master’s degree in International Health Management from Imperial College London
He has been associated with Shalby since October 5, 2013, providing over 10 years of industry experience
Shareholder approval for the appointment is scheduled for the 22nd AGM on September 10, 2026
👀 What to Watch
Watch for shareholder approval at the AGM on September 10, 2026, and monitor if this leadership transition accelerates the 50% YoY growth target for the MedTech division.
Shalby Q1 Revenue Grows 11.7% YoY to ₹331 Cr; Appoints Shanay Shah as Whole-Time Director
Shalby Limited reported a consolidated revenue of ₹331.22 Cr for Q1 FY27, an 11.7% increase over the ₹296.43 Cr reported in Q1 FY26. Profit Before Tax (PBT) for the quarter stood at ₹19.69 Cr, a decline of 13% YoY from ₹22.65 Cr, primarily impacted by a ₹11.48 Cr loss in the Manufacturing (MedTech) segment. The board approved the appointment of Mr. Shanay Vikram Shah as a Whole-Time Director for a five-year term. Additionally, the company completed the acquisition of the remaining 0.67% stake in its step-down subsidiary, SGTPL, for SGD 20,000, making it a 100% subsidiary.
Confidence: HIGH
What changedShalby reported its Q1 FY27 financial performance and elevated a promoter-family member to the board as a Whole-Time Director.
Why it mattersThe results highlight a growing core hospital business but persistent operational challenges in the MedTech division. The management change signals a formalization of succession and leadership roles within the promoter family.
Q1 FY27 Revenue: ₹331.22 CrQ1 FY27 PBT: ₹19.69 CrYoY Revenue Growth: 11.7%Manufacturing Segment Loss: ₹11.48 CrSGTPL Acquisition Cost: SGD 20,000Revenue vs TTM Revenue: 29.0%
📅 Short termThe stock may face pressure due to the 13% YoY decline in PBT and the continued losses in the implant manufacturing segment.
📈 Long termLong-term value depends on the company's ability to scale its MedTech division to break-even and improve occupancy at its newer hospital units like Sanar.
⚠ Risk flags
- Persistent losses in the Manufacturing & Trading of Implants segment
- Related-party transaction for the acquisition of SGTPL shares from promoters
- High P/E ratio of 49.0 relative to current profit growth
Key Highlights
Consolidated revenue for Q1 FY27 reached ₹331.22 Cr, up 11.7% YoY from ₹296.43 Cr.
Healthcare Services segment revenue grew to ₹288.81 Cr, contributing 87% of total revenue.
Manufacturing & Trading of Implants segment reported a loss of ₹11.48 Cr, widening from a ₹9.91 Cr loss in Q1 FY26.
Appointment of Mr. Shanay Vikram Shah (Promoter group) as Whole-Time Director for 5 years effective August 12, 2026.
Acquisition of 10,000 shares (0.67%) of Shalby Global Technologies Pte. Ltd. for SGD 20,000 from promoters.
👀 What to Watch
Investors should monitor the path to profitability for the MedTech (Implant) segment, which remains a drag on consolidated margins despite revenue growth. Watch for the upcoming AGM on September 10, 2026, for shareholder approval of the new director appointment and further strategic updates.
₹129.70 Cr Working Capital Facility Approved for Shalby and US Subsidiary
Shalby Limited has approved availing working capital facilities totaling ₹129.70 crore from Kotak Mahindra Bank. A significant portion, ₹119.70 crore, is dedicated to its US-based step-down subsidiary, Shalby Advanced Technologies, Inc., to support its operational requirements. The parent company will utilize the remaining ₹10 crore through Working Capital Demand Loans or Cash Credit. This total facility represents approximately 11.4% of the company's TTM revenue and is significant relative to its existing debt of ₹131 crore.
Confidence: HIGH
What changedShalby has secured new credit lines totaling ₹129.70 crore, shifting its financing focus toward its US-based MedTech operations.
Why it mattersThe US subsidiary (SAT Inc.) is a critical growth engine for Shalby's diversification into implants; securing this liquidity is essential for managing its high inventory levels and scaling production.
Total Facility Amount: ₹129.70 croreUS Subsidiary Portion: ₹119.70 croreFacility vs TTM Revenue: ~11.4%Facility vs Existing Debt: ~99%Parent Company Portion: ₹10 crore
📅 Short termNeutral impact expected on the stock price as this is a routine operational financing arrangement to support working capital.
📈 Long termStructural support for the MedTech division's expansion in the US market, which is vital for achieving the company's long-term 16-20% growth guidance.
⚠ Risk flags
- Increased interest expense
- High inventory levels in the MedTech segment requiring capital infusion
- Reliance on US market performance for debt servicing
Key Highlights
Total working capital facility approved for ₹129.70 crore from Kotak Mahindra Bank.
₹119.70 crore allocated specifically for the US step-down subsidiary, Shalby Advanced Technologies, Inc.
₹10 crore sanctioned for the parent company via WCDL/Cash Credit facilities.
The total facility amount is equivalent to ~10.4% of the company's current Net Worth of ₹1247 crore.
The facility supports the MedTech segment, which the company expects to grow by 50% YoY.
👀 What to Watch
Investors should monitor the MedTech segment's revenue growth in upcoming quarters to ensure the increased working capital is translating into the projected 50% YoY growth. Additionally, check for any significant rise in finance costs in the next P&L statement.
ICRA Downgrades Shalby Ltd to [ICRA]A; Outlook Revised to Stable for Rs 830 Cr Facilities
ICRA has downgraded Shalby Limited's long-term credit rating from [ICRA]A+ to [ICRA]A for bank facilities totaling Rs 830 crore. While the rating was lowered, the outlook was revised from 'Negative' to 'Stable', suggesting a steady credit profile at the new rating level. This action follows a significant drop in profitability, with FY25 PAT falling to Rs 1.92 crore from Rs 83.46 crore in FY24. The rated amount is substantial, representing approximately 73% of the company's TTM revenue.
Confidence: HIGH
What changedICRA has lowered Shalby's credit rating by one notch to [ICRA]A while simultaneously removing the 'Negative' outlook in favor of a 'Stable' one.
Why it mattersA credit rating downgrade typically leads to higher borrowing costs and reflects increased financial risk, likely stemming from the sharp decline in net profit and margins observed over the last fiscal year.
Total Rated Amount: Rs 830 croreRated Amount vs TTM Revenue: ~72.7%Non-fund based SBLC: Rs 453.73 croreUnallocated Limits: Rs 238.27 croreTTM PAT: Rs 34 crore
📅 Short termThe market may react negatively to the downgrade in the coming days, as it confirms deteriorating credit metrics despite the stabilization of the outlook.
📈 Long termThe company needs to successfully integrate recent acquisitions (HHPL, PKHPL) and scale its MedTech division to restore the margins required for a rating upgrade.
⚠ Risk flags
- Significant margin compression (19% to 12% OPM)
- Low occupancy at key expansion units
- High unallocated credit limits
Key Highlights
Long-term rating downgraded from [ICRA]A+ to [ICRA]A for Rs 830 crore total facilities.
Outlook revised from Negative to Stable, indicating credit stability at the current level.
Rated facilities include Rs 453.73 crore in Standby Letters of Credit (SBLC) and Rs 238.27 crore in unallocated limits.
The total rated amount of Rs 830 crore is ~73% of the TTM revenue of Rs 1,141 crore.
Downgrade follows a period where OPM compressed from 18.98% in FY24 to 12.2% in FY25.
👀 What to Watch
Investors should monitor the company's quarterly operating margins and occupancy levels at the Sanar unit (previously reported at a low 21%) to see if profitability recovers to support the current debt profile.
Shalby Q4 FY26: PAT Reaches ₹18.5 Cr; MedTech Segment Turns EBITDA Positive
Shalby Limited reported a strong Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹295.5 crores and EBITDA rising 43.1% to ₹37.4 crores. The company achieved a significant turnaround in profitability, posting a PAT of ₹18.5 crores compared to a loss of ₹12.2 crores in the previous year, aided by a transition to a new tax regime. The MedTech (implant) business showed robust growth, with annual revenue crossing ₹135 crores and turning EBITDA positive at ₹6.7 crores for the full year. Despite geopolitical headwinds affecting the Gurugram unit's international patient flow, overall operational metrics like ARPOB and occupancy remained stable.
Key Highlights
Consolidated EBITDA grew by 43.1% YoY to ₹37.4 crores in Q4 FY26, with margins expanding to 12.7%.
Shalby MedTech revenue increased by 46% in FY26 to ₹135 crores, achieving a full-year positive EBITDA of ₹6.7 crores.
Standalone ARPOB improved by 2.7% to ₹42,689, while group-level occupancy stood at 48% (50% excluding the Gurugram unit).
The company successfully completed 70 transplants, including 51 kidney and 19 liver transplants, during FY26.
Maintained a healthy balance sheet with a gearing ratio of 0.44x and net debt of ₹446.2 crores.
👀 What to Watch
Investors should focus on the successful turnaround of the MedTech segment and the recurring tax benefits which are expected to sustain higher PAT margins. Monitor the recovery of international patient volumes at the Gurugram facility as geopolitical tensions ease.
Shalby Q4 FY26 Consolidated PAT Surges 251% YoY to ₹185 Mn; EBITDA Up 43%
Shalby Limited reported a robust Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹2,955 mn. The company achieved a significant 43.1% YoY growth in consolidated EBITDA to ₹374 mn, while PAT reached ₹185 mn, largely supported by the transition to a new tax regime. Operational metrics in the hospital business showed improvement with occupancy rising to 48% from 45% YoY, although surgery counts dipped by 6.7%. The MedTech segment continues to diversify the revenue stream, contributing 13.5% to the total quarterly turnover.
Key Highlights
Consolidated Q4 FY26 Revenue increased 9.4% YoY to ₹2,955 mn; Full-year FY26 revenue stood at ₹11,682 mn.
Consolidated EBITDA for Q4 FY26 rose 43.1% YoY to ₹374 mn, with margins improving to 12.7% from 9.7% YoY.
Hospital occupancy rate improved to 48% in Q4 FY26 vs 45% in Q4 FY25, while ARPOB grew 2.7% to ₹42,689.
Shalby MedTech (Implant business) generated ₹400.4 mn in revenue during the quarter, accounting for 13.55% of consolidated revenue.
Consolidated Net Debt as of March 31, 2026, stood at ₹4,462 mn with an annualized ROCE of 7.3%.
👀 What to Watch
Investors should focus on the company's ability to scale the high-margin MedTech business and the turnaround of the Shalby International (Delhi-NCR) unit, which is currently EBITDA negative. The core hospital business remains a steady cash generator with improving occupancy levels.
Shalby Ltd FY26 Standalone Revenue Grows to ₹8,986 Million; No Dividend Recommended
Shalby Limited reported a steady growth in its standalone operations for the financial year ended March 31, 2026, with revenue from operations reaching ₹8,985.58 million compared to ₹8,688.60 million in FY25. The fourth quarter (Q4 FY26) saw revenue of ₹2,248.54 million, reflecting a 5.3% sequential growth from Q3 FY26. Despite the revenue growth, the Board has opted not to recommend any dividend for the financial year 2025-26. Additionally, the company has appointed M/s. Borad Sanjay B & Associates as Cost Auditors for the upcoming fiscal year.
Key Highlights
Standalone Revenue from Operations for FY26 rose to ₹8,985.58 million from ₹8,688.60 million in the previous year.
Q4 FY26 Revenue stood at ₹2,248.54 million, up from ₹2,135.09 million in Q3 FY26 and ₹2,070.03 million in Q4 FY25.
Total Standalone Income for the full year FY26 reached ₹9,234.15 million.
The Board of Directors did not recommend any dividend for the financial year 2025-26.
The 22nd Annual General Meeting (AGM) of the company is scheduled for September 10, 2026.
👀 What to Watch
Investors should review the full consolidated financial statements to assess overall group profitability and margin trends. The decision to skip dividends suggests the company may be prioritizing capital conservation or reinvestment into operations.
Vijay Kedia Resigns as Independent Director of Shalby Limited Effective April 30, 2026
Mr. Vijay Kishanlal Kedia has tendered his resignation as an Independent Director of Shalby Limited, effective from the close of business hours on April 30, 2026. He cited increasing professional commitments and time constraints as the primary reasons for stepping down after a three-year association with the board. The company and Mr. Kedia have confirmed there are no other material reasons for this departure. While Mr. Kedia is a high-profile investor, his exit from the board appears to be a routine transition rather than a reflection of internal issues.
Key Highlights
Resignation of Mr. Vijay Kishanlal Kedia (DIN: 00230480) effective April 30, 2026
Reason for departure cited as increasing professional commitments and time constraints
Mr. Kedia served on the Board of Directors for a period of approximately 3 years
Confirmation provided that no other material reasons exist for the resignation
Mr. Kedia continues to hold a Non-Executive Directorship at Atul Auto Ltd
👀 What to Watch
Investors should treat this as a routine board change as no governance concerns were raised. Monitor the company's future board appointments to ensure continued strong independent oversight.
Shalby Issues USD 13.27 Million SBLC for US Step-Down Subsidiary
Shalby Limited has issued a Standby Letter of Credit (SBLC) for an amount up to USD 13.27 million through IndusInd Bank. The beneficiary of this financial guarantee is Shalby Advanced Technologies, Inc. (SAT Inc.), which is the company's step-down subsidiary based in the USA. This move is intended to help the overseas unit secure credit facilities for its operational requirements. While the company expects no immediate material financial impact on its own operations, it represents a significant financial commitment to its international expansion.
Key Highlights
Issuance of Standby Letter of Credit (SBLC) totaling up to USD 13.27 million
Beneficiary is Shalby Advanced Technologies, Inc., a USA-based step-down subsidiary
Financial facility facilitated through IndusInd Bank Limited
Aims to assist the subsidiary in obtaining credit facilities for business needs
Transaction confirmed to be at arm's length with no promoter group interest
👀 What to Watch
Investors should monitor the operational progress of the US subsidiary, as the parent company has now increased its contingent liability to support the unit's creditworthiness. No immediate portfolio changes are necessary based on this routine financial support disclosure.
Shalby Launches Advanced Oncology and Radiotherapy Department at Krishna Shalby Hospital
Shalby Limited has announced the inauguration of a specialized Oncology Department at its Krishna Shalby Hospital in Ahmedabad. This new facility includes advanced Radiotherapy services, allowing for comprehensive cancer treatment under one roof. The department is staffed by a multidisciplinary team of medical, radiation, and surgical oncologists to provide integrated care. This expansion into high-specialty services is expected to enhance the hospital's service mix and competitive positioning in the Ahmedabad region.
Key Highlights
Inauguration of a new Oncology Department at Krishna Shalby Hospital, Ahmedabad
Addition of advanced Radiotherapy facilities to provide integrated cancer care
Deployment of a multidisciplinary team including medical, radiation, and surgical oncologists
Strategic focus on providing comprehensive diagnosis and treatment at a single location to improve patient outcomes
👀 What to Watch
Investors should view this as a positive development as oncology is a high-margin specialty that can drive higher Average Revenue Per Occupied Bed (ARPOB). Monitor the company's upcoming quarterly results for improvements in specialized treatment volumes.
Shalby Launches Advanced Oncology and Radiotherapy Department at Surat Hospital
Shalby Limited has inaugurated a comprehensive Oncology Department at its Surat multi-specialty hospital. The new facility includes advanced radiotherapy services, enabling the hospital to provide integrated cancer care across medical, surgical, and radiation oncology. This expansion targets the South Gujarat region, aiming to provide specialized diagnosis and treatment under one roof. The addition of high-margin oncology services is expected to enhance the hospital's service mix and potentially improve its Average Revenue Per Occupied Bed (ARPOB).
Key Highlights
Inauguration of a dedicated Oncology Department at Shalby Multi-Specialty Hospital, Surat
Introduction of advanced Radiotherapy facilities for comprehensive cancer treatment
Integrated care model featuring medical, radiation, and surgical oncology teams
Strategic expansion to capture demand for specialized cancer care in the South Gujarat region
👀 What to Watch
Investors should view this as a positive operational development that could boost high-margin revenue for the Surat unit. Monitor future quarterly results for improvements in ARPOB and occupancy driven by these specialized services.
Shalby Subsidiary PK Healthcare Receives NABH Accreditation Valid Until 2030
Shalby Limited's subsidiary, PK Healthcare Private Limited (Shalby International Hospitals) located in Gurugram, has been granted accreditation by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). The accreditation follows the 6th Edition Standards, which focus on patient safety, clinical governance, and risk management. This certification is valid for a period of four years, extending until 2030. Such accreditations are critical for healthcare providers to maintain quality benchmarks and attract corporate and insurance-linked patients.
Key Highlights
PK Healthcare Pvt Ltd (Gurugram) granted NABH accreditation under the rigorous 6th Edition Standards.
The accreditation is valid for a long-term duration until the year 2030.
Framework emphasizes patient safety protocols, clinical governance, and continuous quality improvement.
Accreditation strengthens the hospital's position in evidence-based clinical care and infection control.
👀 What to Watch
Investors should view this as a positive operational milestone that validates the quality of healthcare services at Shalby's Gurugram facility. This accreditation is likely to improve the hospital's reputation and operational efficiency, supporting long-term revenue growth.
Shalby Increases Stake in Subsidiary PK Healthcare to 91.13% via Rs 59.6 Cr Rights Issue
Shalby Limited has increased its stake in its subsidiary, PK Healthcare Private Limited (PKHPL), from 87.26% to 91.13%. The company invested approximately Rs 59.60 crore by subscribing to 5.96 crore equity shares at a price of Rs 10 per share through a rights issue. The capital infusion will be utilized by PKHPL for debt repayment and working capital requirements. PKHPL, which focuses on the Delhi/NCR healthcare market, reported a turnover of Rs 91.19 crore in FY 2024-25.
Key Highlights
Acquired 5,96,01,950 equity shares of PK Healthcare at Rs 10 per share
Total investment amount stands at Rs 59,60,19,500
Shalby's shareholding in PKHPL increased from 87.26% to 91.13%
Funds will be used by the subsidiary for debt repayment and working capital
PKHPL's turnover grew from Rs 67.36 crore in FY23 to Rs 91.19 crore in FY25
👀 What to Watch
This move consolidates control and helps deleverage a key subsidiary in the high-growth Delhi/NCR region. Investors should monitor if this capital infusion leads to improved consolidated margins for Shalby in the coming quarters.
Shalby Q3 FY26: Consolidated PAT Turns Positive at ₹1.3 Cr; MedTech Revenue Jumps 29% YoY
Shalby Limited reported a marginal 0.6% YoY decline in consolidated revenue to ₹279.4 crores for Q3 FY26, while consolidated PAT turned positive at ₹1.3 crores compared to a loss in the previous year. The core hospital business faced headwinds with a 2.6% revenue decline and lower occupancy of 44%, primarily due to ongoing negotiations with major insurance providers. Conversely, the MedTech segment showed strong momentum with 29% revenue growth and achieved EBITDA breakeven for the first time. The company maintains a stable balance sheet with a net debt of ₹408 crores and a low gearing ratio of 0.41x.
Key Highlights
Consolidated PAT improved to ₹1.3 crores from a loss of ₹3 crores in the same quarter last year.
MedTech segment revenue grew 29% YoY to ₹30.38 crores, with EBITDA turning positive at ₹0.7 million.
Hospital standalone revenue declined 2.6% YoY to ₹221 crores with occupancy dropping to 44% from 46%.
ARPOB (Average Revenue Per Occupied Bed) saw a marginal increase of 1.1% YoY to ₹43,171.
Shalby International (Gurgaon) reported revenue of ₹23.9 crores with 51% contribution from international patients.
👀 What to Watch
Investors should monitor the recovery in hospital occupancy once insurance negotiations are finalized and track the scalability of the now-profitable MedTech division. The stock remains a watch as the company transitions its medical implant business from a turnaround to a growth phase.
Shalby Q3 FY26 Results: Consolidated PAT Turns Positive at ₹13 Mn Despite Flat Revenue
Shalby Limited reported a mixed performance for Q3 FY26, with consolidated revenue remaining nearly flat at ₹2,794 million, a marginal 0.6% YoY decline. The company successfully turned around its consolidated bottom line, reporting a PAT of ₹13 million compared to a loss of ₹29.9 million in the year-ago period. However, operational metrics showed weakness, with inpatient counts down 7% and surgery counts down 8.5% YoY. Standalone EBITDA margins also faced significant pressure, contracting to 16.0% from 21.5% in Q3 FY25.
Key Highlights
Consolidated PAT improved to ₹13 million from a loss of ₹29.9 million in Q3 FY25.
Standalone EBITDA margins compressed by 550 bps YoY to 16.0% due to higher operating expenses.
Total surgery counts declined by 8.5% YoY to 6,833, while ARPOB saw a marginal increase of 1.1% to ₹43,171.
MedTech (Implant Business) contributed 10.88% to consolidated revenue, amounting to ₹303.8 million.
Consolidated net debt stood at ₹4,086 million as of December 2025 with an annualized ROCE of 6.7%.
👀 What to Watch
Investors should exercise caution due to the decline in operational volumes and significant margin compression in the core standalone business. While the turnaround in consolidated PAT is positive, the high debt-to-equity ratio of 0.41x and low ROCE warrant a watchful approach.
